DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies. Their lead candidate, DCP-001, is currently in a Phase 2 study for Acute Myeloid Leukemia (AML), building on promising Phase 1 results. With Orphan Medicinal Product designation in the EU, DCPrime aims to provide effective treatments for hematological cancers, including Multiple […]
AmbroSia Therapeutics
Harnessing glycan-modified antigens, AmbroSia Therapeutics aims to modulate immune responses. Their technology has potential applications in a wide variety of auto-immune diseases, oncology and infectious diseases. The initial focus is on the development of an immune modulating therapeutic for Type 1 Diabetes, for which preclinical proof-of-concept has been shown.
Regenesance
Regenesance focuses on antibody engineering to treat neurodegenerative diseases and immune-mediated disorders. The company licenses its technology to Complement Pharma, aiming to develop therapies for conditions like ALS and multiple sclerosis. The company leverages groundbreaking research to improve patient outcomes.
